Gifu, Japan

Yusuke Maeda

This inventor holds 1 USPTO granted patent. Top assignees: National University Corporation Tokai National Higher Education and Research System, Yamasa Corporation. Active years: 2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Yusuke Maeda. Retrieved from https://idiyas.com/inventor/yusuke-maeda-f323h4gm

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2023

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Yusuke Maeda: Innovator in Nucleoside Derivatives

Introduction

Yusuke Maeda is a notable inventor based in Gifu, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of nucleoside derivatives. His work focuses on creating more practical solutions for RNA pharmaceuticals.

Latest Patents

Yusuke Maeda holds a patent for a nucleoside derivative and its applications. This invention is represented by specific formulas that enhance the practicality of nucleosides for various pharmaceutical uses. The patent details a nucleoside that can be modified in several ways, making it versatile for different applications.

Career Highlights

Throughout his career, Yusuke Maeda has worked with reputable organizations, including Yamasa Corporation and the National University Corporation Tokai National Higher Education and Research System. His experience in these institutions has contributed to his expertise in the field of nucleoside research.

Collaborations

Yusuke Maeda has collaborated with notable colleagues such as Yoshihito Ueno and Ryohei Kajino. These partnerships have likely enriched his research and development efforts in nucleoside derivatives.

Conclusion

Yusuke Maeda's innovative work in nucleoside derivatives showcases his commitment to advancing pharmaceutical applications. His contributions are significant in the realm of RNA pharmaceuticals, and his patent reflects his expertise and dedication to the field.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…